Miraculins Announces National Accreditation of Pharmacist Education Program on Cardiovascular Risk Assessment with Focus on Skin Cholesterol

March 20, 2013

Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, in conjunction with Pear Healthcare Solutions, today announces the accreditation of a national program for pharmacists with the course name Cardiovascular Risk Assessment: Focus on Non-Invasive Skin Cholesterol Screening.

All Canadian pharmacists are under obligation by their respective provincial authorities to engage in lifelong learning and competency enhancements that supports optimal, patient centered, outcome focused care through medication management and effective pharmacy practice. With the national accreditation of the cardiovascular (CV) risk assessment education program, Canadian pharmacists can now earn credits to meet this requirement by learning about the benefits of providing CV risk assessment onsite, and skin cholesterol's role within that environment as an emerging biomarker in coronary artery disease risk assessment and screening.

The three modules of the program available at www.healthelearning.ca include:
Module 1 - Cardiovascular Risk Assessment Background (0.50 CEU)

Module 2 - Non-invasive Skin Cholesterol Testing as an (0.50 CEU)
Option for CV Risk Assessment

Module 3 - Communication and Action Plans (0.50 CEU)

"The retail pharmacy segment is an important distribution channel for the PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test," said Christopher J. Moreau, President and CEO of Miraculins Inc. "The newly accredited program for cardiovascular risk assessment is another important step forward in educating pharmacists about the science and biology of skin cholesterol and its role in coronary artery disease risk assessment. This will provide a very important educational foundation for pharmacists as we work in parallel towards offering the PreVu POC Test to all potentially at-risk Canadians through additional national, regional and independent pharmacy locations."

Share This Story

Back

"The retail pharmacy segment is an important distribution channel for the PreVuĀ® Non-Invasive Skin Cholesterol Point of Care (POC) Test," said Christopher J. Moreau, President and CEO of Miraculins Inc. "The newly accredited program for cardiovascular risk assessment is another important step forward in educating pharmacists about the science and biology of skin cholesterol and its role in coronary artery disease risk assessment. This will provide a very important educational foundation for pharmacists as we work in parallel towards offering the PreVu POC Test to all potentially at-risk Canadians through additional national, regional and independent pharmacy locations."